<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03936465</url>
  </required_header>
  <id_info>
    <org_study_id>19-040</org_study_id>
    <nct_id>NCT03936465</nct_id>
  </id_info>
  <brief_title>Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitor BMS-986158 in Pediatric Cancer</brief_title>
  <official_title>Phase 1 Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitor BMS-986158 in Pediatric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stand Up To Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is studying an investigational drug called BMS-986158 as a possible&#xD;
      treatment for pediatric solid tumors, lymphoma, or brain tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I clinical trial, which tests the safety of an investigational drug and also&#xD;
      tries to define the appropriate dose of the investigational drug to use for further studies.&#xD;
      &quot;Investigational&quot; means that the drug is being studied.&#xD;
&#xD;
      The FDA (the U.S. Food and Drug Administration) has not approved BMS-986158 as a treatment&#xD;
      for any disease.&#xD;
&#xD;
      BMS-986158 is currently still being studied in adults. This is the first time that BMS-986158&#xD;
      will be evaluated in younger children, though children 12-17 years of age may also be&#xD;
      included in parts of adult studies of BMS-986158.&#xD;
&#xD;
      Research in the laboratory has shown that BMS-986158 may have activity against cancer cells.&#xD;
      BMS-986158 belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain&#xD;
      (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a&#xD;
      process important for cancer cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2019</start_date>
  <completion_date type="Anticipated">July 10, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 10, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity Rate</measure>
    <time_frame>28 days (first cycle)</time_frame>
    <description>Dose limiting toxicity as defined in protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Rate of Toxicities of BMS-986158</measure>
    <time_frame>2 years</time_frame>
    <description>Adverse events coded using CTCAE version 5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>2 years</time_frame>
    <description>Objective response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of BMS-986158</measure>
    <time_frame>2 years</time_frame>
    <description>Plasma concentrations of BMS-986158</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of BMS-986158</measure>
    <time_frame>2 years</time_frame>
    <description>Gene expression levels in peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Markers of Response</measure>
    <time_frame>2 years</time_frame>
    <description>Levels of ctDNA in peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF Markers of Response</measure>
    <time_frame>2 years</time_frame>
    <description>Levels of ctDNA in CSF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Markers of Response</measure>
    <time_frame>2 years</time_frame>
    <description>Levels of Myc proteins in tumor</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Solid Tumor, Childhood</condition>
  <condition>Lymphoma</condition>
  <condition>Brain Tumor, Pediatric</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive BMS-986158 monotherapy orally for 5 days on / 2 days off per week in 28-day cycles.&#xD;
Patients with unselected relapsed or refractory solid tumors or lymphoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive BMS-986158 monotherapy orally for 5 days on / 2 days off per week in 28-day cycles.&#xD;
Patients with relapsed or refractory solid tumors, lymphoma, or CNS tumors that have defined molecular features predicted to increase sensitivity to BET inhibition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986158</intervention_name>
    <description>BMS-986158 belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≤ 21 years at time of enrollment. Note the requirement in section 3.1.6 that all&#xD;
             patients must be able to swallow intact capsules.&#xD;
&#xD;
          -  Karnofsky performance status ≥ 50% for patients ≥16 years of age or Lansky ≥ 50% for&#xD;
             patients &lt;16 years of age (see Appendix A)&#xD;
&#xD;
          -  Diagnosis requirement&#xD;
&#xD;
               -  Participants must have evaluable or measurable disease (see Section 11).&#xD;
&#xD;
               -  Must have disease that is relapsed or refractory and for which standard curative&#xD;
                  measures do not exist or are no longer effective.&#xD;
&#xD;
               -  For Cohort A, participants must have histologically confirmed non-CNS primary&#xD;
                  solid tumors or lymphoma based upon biopsy or surgery at relapse/progression.&#xD;
                  Patients without biopsy or surgery at relapse/progression and with tissue only&#xD;
                  available from initial diagnosis may still be considered after discussion with&#xD;
                  the overall Primary Investigator.&#xD;
&#xD;
               -  For Cohort B, participants must have histologically confirmed solid tumors,&#xD;
                  lymphoma, or primary CNS tumor based upon biopsy or surgery at&#xD;
                  relapse/progression as well as documentation of one of the following confirmed&#xD;
                  tumor molecular features obtained in a laboratory certified to return results for&#xD;
                  clinical purposes. Patients without biopsy or surgery at relapse/progression and&#xD;
                  with tissue only available from initial diagnosis may still be considered after&#xD;
                  discussion with the overall Primary Investigator.&#xD;
&#xD;
               -  MYCN amplification or high copy number gain&#xD;
&#xD;
               -  MYC amplification or high copy number gain&#xD;
&#xD;
               -  Translocation involving MYC or MYCN&#xD;
&#xD;
               -  Translocation involving BRD4 or BRD3&#xD;
&#xD;
          -  Patients must have fully recovered from the acute toxic effects of all prior&#xD;
             anti-cancer therapy except organ function as noted in Section 3.1.5. Patients must&#xD;
             meet the following minimum washout periods prior to enrollment:&#xD;
&#xD;
          -  Myelosuppressive chemotherapy: At least 14 days after the last dose of&#xD;
             myelosuppressive chemotherapy (42 days for nitrosourea or mitomycin C).&#xD;
&#xD;
          -  Radiotherapy:&#xD;
&#xD;
               -  At least 14 days after local XRT (small port, including cranial radiation);&#xD;
&#xD;
               -  At least 90 days must have elapsed after prior TBI, craniospinal XRT or if &gt;50%&#xD;
                  radiation of pelvis;&#xD;
&#xD;
               -  At least 42 days must have elapsed if other substantial BM radiation;&#xD;
&#xD;
               -  At least 42 days must have passed since last MIBG or other radionuclide therapy.&#xD;
&#xD;
          -  Small molecule biologic therapy: At least 7 days following the last dose of a small&#xD;
             molecule biologic agent. For agents with known adverse events occurring beyond 7 days,&#xD;
             this duration must be extended beyond the time in which adverse events are known to&#xD;
             occur. If extended duration is required, this must be discussed with and approved by&#xD;
             the overall PI.&#xD;
&#xD;
          -  Monoclonal antibody: At least 28 days must have elapsed after the last dose of&#xD;
             therapeutic monoclonal antibody.&#xD;
&#xD;
          -  Myeloid growth factors: At least 14 days following the last dose of long-acting growth&#xD;
             factor (e.g. Neulasta) or 7 days following short-acting growth factor.&#xD;
&#xD;
          -  Autologous hematopoietic stem cell transplant and stem cell boost: Patients must be at&#xD;
             least 60 days from day 0 of an autologous stem cell transplant or autologous stem cell&#xD;
             boost.&#xD;
&#xD;
          -  Cellular therapies (including CAR-T cells) and other non-cellular, non-antibody&#xD;
             immunotherapies (e.g., vaccines): At least 42 days must have elapsed after last dose.&#xD;
&#xD;
          -  Major Surgery: At least 2 weeks from prior major surgical procedure. Note: Major&#xD;
             surgical procedure will be considered all surgical procedures aside from the&#xD;
             following: Biopsy; central line placement/removal; bone marrow aspirate/biopsy; lumbar&#xD;
             puncture; dental procedures; gastrostomy tube placement; and VP shunt&#xD;
             placement/revision.&#xD;
&#xD;
          -  BET inhibitors: Patients must not have received prior treatment with a BET inhibitor.&#xD;
&#xD;
          -  Participants must have normal organ function as defined below.&#xD;
&#xD;
          -  Bone Marrow Function&#xD;
&#xD;
          -  For Patients without Documented Bone Marrow Involvement by Disease:&#xD;
&#xD;
               -  Hemoglobin &gt; 8 g/dL (may be transfused)&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,000 /uL&#xD;
&#xD;
               -  Platelets ≥ 100,000 /uL and transfusion independent, defined as not receiving a&#xD;
                  platelet transfusion for at least 5 days prior to CBC documenting eligibility.&#xD;
&#xD;
          -  For Patients with Documented Bone Marrow Involvement by Disease:&#xD;
&#xD;
               -  Hemoglobin &gt; 8 g/dL (may be transfused)&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 750 /uL&#xD;
&#xD;
               -  Platelets ≥ 75,000 /uL and transfusion independent, defined as not receiving a&#xD;
                  platelet transfusion for at least 5 days prior to CBC documenting eligibility.&#xD;
&#xD;
          -  Hepatic Function:&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x upper limit of normal for age (patients with known&#xD;
                  Gilbert's may be considered after discussion with overall PI and if direct&#xD;
                  bilirubin is at or below the upper limit of normal for age)&#xD;
&#xD;
               -  ALT (SGPT) ≤ 3 x upper limit of normal (135 U/L) For the purpose of this study,&#xD;
                  the ULN for ALT is 45 U/L&#xD;
&#xD;
               -  Serum albumin &gt; 2 g/dL&#xD;
&#xD;
          -  Adequate Pancreatic Function:&#xD;
&#xD;
             --Lipase &lt; upper limit of normal&#xD;
&#xD;
          -  Adequate GI Function:&#xD;
&#xD;
             --Diarrhea &lt; grade 1 by CTCAE version 5&#xD;
&#xD;
          -  Coagulation Factors:&#xD;
&#xD;
               -  International Normalized Ratio (INR) &lt; 1.5&#xD;
&#xD;
               -  Partial thromboplastin time (PTT) &lt; 1.5 times upper limit of normal&#xD;
&#xD;
          -  For patients having labs drawn via heparinized catheters, it is important to request&#xD;
             heparin-absorbed values.&#xD;
&#xD;
          -  Adequate Cardiac Function:&#xD;
&#xD;
             --QTc &lt; 480 msec&#xD;
&#xD;
          -  Renal Function:&#xD;
&#xD;
               -  A serum creatinine within protocol limits based on age/sex.&#xD;
&#xD;
        OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min/1.73 m2 for participants with creatinine levels&#xD;
             greater than the above age/sex maximum allowed values.&#xD;
&#xD;
          -  Able to swallow intact capsules.&#xD;
&#xD;
          -  Patient (or parent or legally authorized representative, if minor) is able to&#xD;
             understand and willing to provide informed consent, using an institutionally approved&#xD;
             informed consent procedure.&#xD;
&#xD;
          -  Participants of childbearing or child-fathering potential must agree to use adequate&#xD;
             contraception throughout their participation following the guidance in Appendix H.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior solid organ or allogeneic stem cell transplantation.&#xD;
&#xD;
          -  Patients with primary or metastatic CNS tumors, except:&#xD;
&#xD;
               -  Patients with primary CNS tumor meeting definition for Cohort B;&#xD;
&#xD;
               -  Patients with a history of CNS metastatic disease that has been resected and/or&#xD;
                  radiated without evidence of active CNS disease for 3 months preceding&#xD;
                  enrollment;&#xD;
&#xD;
               -  Patients with lymphoma and CSF involvement.&#xD;
&#xD;
          -  Patients receiving any of the following prohibited foods and medications:&#xD;
&#xD;
               -  Agents listed in Appendix B within 7 days prior to enrollment&#xD;
&#xD;
               -  Grapefruit or Seville oranges and/or their juices within 7 days prior to&#xD;
                  enrollment&#xD;
&#xD;
               -  Non-steroidal anti-inflammatory drugs, oral anticoagulants, and therapeutic&#xD;
                  heparins (unfractionated or low molecular weight heparin) at the time of&#xD;
                  enrollment. Note: Use of heparin to maintain patency of a central or peripheral&#xD;
                  catheter is allowed&#xD;
&#xD;
               -  Other investigational agents being administered under an IND.&#xD;
&#xD;
          -  Pregnant participants will not be entered on this study given that the effects of&#xD;
             BMS-986158 on the developing human fetus are unknown. Female participants of&#xD;
             childbearing potential must have a documented negative pregnancy exam within 24 hours&#xD;
             prior to dosing.&#xD;
&#xD;
          -  Breastfeeding mothers are not eligible, because there is an unknown risk for adverse&#xD;
             events in nursing infants secondary to treatment of the mother with BMS-986158.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to BMS-986158.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or&#xD;
             uncontrolled infection, symptomatic congestive heart failure, unstable angina&#xD;
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements.&#xD;
&#xD;
          -  Patients with a known history of HIV, hepatitis B, and/or hepatitis C (testing not&#xD;
             required as part of screening).&#xD;
&#xD;
          -  Patients with gastrointestinal disease or disorder that could interfere with&#xD;
             absorption of BMS-986158, such as bowel obstruction or inflammatory bowel disease.&#xD;
&#xD;
          -  Patients with a body surface area &lt; 0.3 m2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven G. DuBois, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven G DuBois, MD,MS</last_name>
    <phone>617-632-5460</phone>
    <email>steven_dubois@dfci.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven G. DuBois, MD, MS</last_name>
      <phone>617-632-5460</phone>
      <email>steven_dubois@dfci.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jeffrey Czaplinski</last_name>
      <phone>617-632-5063</phone>
      <email>jeffreyt_czaplinski@dfci.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Steven G. DuBois, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C.S. Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajen Mody, MD, MS</last_name>
      <phone>734-764-7126</phone>
      <email>rmody@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ian Wolfe</last_name>
      <phone>(734) 232-4046</phone>
      <email>iawolfe@med.umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rajen Mody, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Van Mater, MD, PhD</last_name>
      <phone>919-681-3401</phone>
      <email>david.vanmater@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tyler Ray</last_name>
      <phone>(919) 681-9186</phone>
      <email>tyler.ray@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David Van Mater, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trent Hummel, MD</last_name>
      <email>trent.hummel@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Bidwell</last_name>
      <phone>(513) 636-0087</phone>
      <email>andrea.bidwell@cchmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Trent Hummel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Morgenstern, MD</last_name>
      <phone>(416) 813-7654</phone>
      <phone_ext>227565</phone_ext>
      <email>daniel.morgenstern@sickkids.ca</email>
    </contact>
    <contact_backup>
      <last_name>Rosie Wilson</last_name>
      <phone>(416) 813-7654</phone>
      <phone_ext>202043</phone_ext>
      <email>rosie.wilson@sickkids.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Morgenstern, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 30, 2019</study_first_submitted>
  <study_first_submitted_qc>May 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2019</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Steven DuBois</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Solid Tumor</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Neuroblastoma</keyword>
  <keyword>Sarcoma</keyword>
  <keyword>Medulloblastoma</keyword>
  <keyword>MYC</keyword>
  <keyword>MYCN</keyword>
  <keyword>BRD4</keyword>
  <keyword>BET inhibitor</keyword>
  <keyword>Bromodomain</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

